Semaglutide helps lower HbA1c, body weight of T2D patients
03 Feb 2020
byStephen Padilla
Treatment with semaglutide leads to clinically significant decreases in haemoglobin A1C (HbA1c) and body weight in patients with type 2 diabetes (T2D) across the SUSTAIN 1–7 trials, regardless of race and ethnicity, results of a posthoc analysis have shown.
Semaglutide helps lower HbA1c, body weight of T2D patients
03 Feb 2020